HomeMedical SpecialtiesPulmonary and RespirologyProlonged cough? In most cases, patience is the treatment

Prolonged cough? In most cases, patience is the treatment

Published on

Coughing after a respiratory infection is common and, in most cases, will resolve with time, according to an article in CMAJ (Canadian Medical Association Journal).

With the recent bout of respiratory infections across Canada, many people are suffering from a postinfectious cough, or a cough that lasts for weeks after the initial infection has resolved.

“Reassuring patients that postinfectious cough is time limited and self resolving is important and can reduce unnecessary and costly prescriptions, such as asthma puffers or antibiotics,” said Dr. Kevin Liang, a family physician and clinical instructor in the Department of Family Practice at the University of British Columbia, Vancouver, BC. “Most postinfectious cough symptoms will improve without medication.”

Key points about postinfectious cough:

1. Postinfectious coughs are common, affecting about 11 per cent to 25 per cent of adults after a respiratory infection and can last up to 8 weeks.

2. Diagnosis requires an earlier respiratory infection and exclusion of other postinfectious cough mimics, such as asthma and chronic obstructive pulmonary disease.

3. Check for red flags and cough duration. Symptoms such as swallowing difficulty, excessive shortness of breath, and coughing up blood may require investigation. Red flags include a history of recurrent pneumonia or an extended history of smoking, and coughs lasting longer than 8 weeks need further assessment.

4. There is no good evidence for a medication that works to stop postinfectious cough. Evidence shows little benefit with inhalers or oral medications to treat a cough. These medications can be quite costly and cause unwanted side effects as well.

5. Patient reassurance and education are critical. Clinicians should advise patients to arrange a follow-up appointment for further investigation if their cough has not resolved within 8 weeks or if new symptoms appear.

“Postinfectious cough in adults” was published February 12, 2024.

Latest articles

New approach opens door to better-targeted treatments and faster drug discovery for complex diseases

McGill University researchers have developed an artificial intelligence tool that can identify small groups of cells most responsible...

Canadian Cancer Society urges lowering colorectal cancer screening age to 45

The Canadian Cancer Society (CCS) is calling on provinces and territories to lower the...

Unleashing natural killer cells against cancer

Researchers at McGill University have developed a new strategy to enhance natural killer (NK) cells, enabling them to better penetrate tumour defenses and destroy cancer cells. Using small-molecule drugs to temporarily boost NK cell activity—rather than permanent genetic modification—the approach showed strong results against multiple hard-to-treat cancers in preclinical studies. The scalable, ready-to-use therapy could make immunotherapy faster, safer, and more accessible, with future clinical trials planned for aggressive cancers like acute myeloid leukemia.

Doctors report false health information, lack of health data sharing put patient care at risk

Canada's doctors are concerned that false health information and disconnected health systems are putting...

More like this

New approach opens door to better-targeted treatments and faster drug discovery for complex diseases

McGill University researchers have developed an artificial intelligence tool that can identify small groups of cells most responsible...

Canadian Cancer Society urges lowering colorectal cancer screening age to 45

The Canadian Cancer Society (CCS) is calling on provinces and territories to lower the...

Unleashing natural killer cells against cancer

Researchers at McGill University have developed a new strategy to enhance natural killer (NK) cells, enabling them to better penetrate tumour defenses and destroy cancer cells. Using small-molecule drugs to temporarily boost NK cell activity—rather than permanent genetic modification—the approach showed strong results against multiple hard-to-treat cancers in preclinical studies. The scalable, ready-to-use therapy could make immunotherapy faster, safer, and more accessible, with future clinical trials planned for aggressive cancers like acute myeloid leukemia.

An individualized and equitable approach: Pregnancy care for people with disabilities

HN Summary • Sunnybrook’s Accessible Care Pregnancy Clinic provides individualized, fully accessible care for people...

First-in-Canada case of sustained HIV remission

HN Summary • A first-in-Canada case shows a patient achieving sustained HIV remission following a...

UHN researchers investigate new therapies as colon cancer rises among young patients

HN Summary • Colorectal cancer is rising among younger adults, prompting UHN researchers to investigate...